Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fate Therapeutics Inc (FATE) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Fate Therapeutics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1434316.
Total stock buying since 2015: $136,974,145.
Total stock sales since 2015: $126,039,726.
Total stock option exercises since 2015: $6,425,126.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 43,842 | $56,398 | 0 | $0 |
| 2024 | 0 | $0 | 51,228 | $221,373 | 0 | $0 |
| 2023 | 471,648 | $2,724,190 | 348,665 | $1,924,918 | 28,461 | $38,991 |
| 2022 | 0 | $0 | 395,110 | $15,633,530 | 297,808 | $1,144,607 |
| 2021 | 327,485 | $27,999,967 | 733,076 | $62,227,285 | 599,796 | $3,500,005 |
| 2020 | 1,412,928 | $39,999,991 | 357,100 | $18,027,262 | 319,614 | $995,001 |
| 2019 | 857,143 | $15,000,002 | 961,955 | $17,342,978 | 229,335 | $561,389 |
| 2018 | 3,703,704 | $50,000,004 | 650,000 | $10,457,057 | 21,054 | $124,113 |
| 2017 | 0 | $0 | 38,484 | $148,925 | 0 | $0 |
| 2016 | 469,922 | $1,249,991 | 0 | $0 | 10,070 | $14,770 |
| 2015 | 0 | $0 | 0 | $0 | 33,000 | $46,250 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 23,503 | $24,961 | 0 | $0 |
| 2025-01 | 0 | $0 | 20,339 | $31,437 | 0 | $0 |
| 2024-08 | 0 | $0 | 633 | $2,677 | 0 | $0 |
| 2024-01 | 0 | $0 | 50,595 | $218,696 | 0 | $0 |
| 2023-12 | 44,630 | $166,023 | 1,585 | $5,547 | 0 | $0 |
| 2023-11 | 0 | $0 | 24,363 | $58,471 | 0 | $0 |
| 2023-08 | 0 | $0 | 5,350 | $15,554 | 0 | $0 |
| 2023-07 | 0 | $0 | 9,036 | $43,797 | 0 | $0 |
| 2023-06 | 0 | $0 | 3,460 | $19,306 | 0 | $0 |
| 2023-04 | 302,339 | $1,860,029 | 304,871 | $1,782,243 | 0 | $0 |
| 2023-01 | 124,679 | $698,138 | 0 | $0 | 28,461 | $38,991 |
| 2022-08 | 0 | $0 | 5,135 | $154,460 | 0 | $0 |
| 2022-07 | 0 | $0 | 64,965 | $2,032,582 | 61,246 | $174,386 |
| 2022-06 | 0 | $0 | 31,606 | $723,846 | 25,000 | $163,750 |
| 2022-04 | 0 | $0 | 69,062 | $2,550,122 | 65,000 | $250,375 |
| 2022-03 | 0 | $0 | 56,562 | $1,917,233 | 56,562 | $119,696 |
| 2022-01 | 0 | $0 | 167,780 | $8,255,287 | 90,000 | $436,400 |
| 2021-12 | 0 | $0 | 48,477 | $2,541,950 | 46,937 | $703,452 |
| 2021-11 | 0 | $0 | 20,000 | $1,085,400 | 20,000 | $54,000 |
| 2021-10 | 0 | $0 | 110,000 | $6,517,750 | 110,000 | $512,090 |
| 2021-09 | 0 | $0 | 44,460 | $2,885,482 | 42,325 | $683,634 |
| 2021-08 | 0 | $0 | 23,474 | $2,068,864 | 20,000 | $96,700 |
| 2021-07 | 0 | $0 | 115,534 | $10,139,547 | 115,534 | $530,764 |
| 2021-06 | 0 | $0 | 25,000 | $2,246,200 | 25,000 | $70,375 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-04 | Valamehr Bahram (President and CEO) | Sale | 14,466 | 1.06 | 15,391 |
| 2025-08-04 | Tahl Cindy (See Remarks) | Sale | 9,037 | 1.06 | 9,570 |
| 2025-01-10 | Bressi Jerome Charles (See Remarks) | Sale | 5,980 | 1.55 | 9,269 |
| 2025-01-10 | Valamehr Bahram (President and CEO) | Sale | 8,705 | 1.54 | 13,405 |
| 2025-01-10 | Tahl Cindy (See Remarks) | Sale | 5,654 | 1.55 | 8,763 |
| 2024-08-06 | Xu Yuan | Sale | 633 | 4.23 | 2,677 |
| 2024-01-29 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 1,849 | 5.00 | 9,245 |
| 2024-01-09 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 7,028 | 4.37 | 30,712 |
| 2024-01-09 | Valamehr Bahram (Chief R&D Officer) | Sale | 11,271 | 4.38 | 49,366 |
| 2024-01-09 | Tahl Cindy (General Counsel and Secretary) | Sale | 10,874 | 4.37 | 47,519 |
| 2024-01-09 | Wolchko J Scott (President and CEO) | Sale | 14,391 | 4.37 | 62,888 |
| 2024-01-02 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 5,182 | 3.66 | 18,966 |
| 2023-12-26 | Green Jeremy | Buy | 44,630 | 3.72 | 166,023 |
| 2023-12-18 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 1,585 | 3.50 | 5,547 |
| 2023-11-09 | Tahl Cindy (General Counsel and Secretary) | Sale | 24,363 | 2.40 | 58,471 |
| 2023-08-18 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 4,718 | 2.80 | 13,210 |
| 2023-08-04 | Xu Yuan (Director) | Sale | 632 | 3.71 | 2,344 |
| 2023-07-05 | Powl Brian T. (Chief Commercial Officer) | Sale | 3,854 | 4.87 | 18,768 |
| 2023-07-05 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 5,182 | 4.83 | 25,029 |
| 2023-06-14 | Xu Yuan (Director) | Sale | 3,460 | 5.58 | 19,306 |
| 2023-04-21 | Green Jeremy | Buy | 256,639 | 6.18 | 1,586,029 |
| 2023-04-20 | Green Jeremy | Buy | 20,000 | 5.99 | 119,800 |
| 2023-04-18 | Chu Yu-waye (Chief Medical Officer) | Sale | 2,532 | 6.55 | 16,584 |
| 2023-04-14 | Green Jeremy | Buy | 25,700 | 6.00 | 154,200 |
| 2023-04-14 | Green Jeremy | Sale | 302,339 | 5.84 | 1,765,659 |
| 2023-01-19 | Mendlein John (Director) | Option Ex | 28,461 | 1.37 | 38,991 |
| 2023-01-13 | Mendlein John (Director) | Buy | 36,631 | 5.43 | 198,906 |
| 2023-01-11 | Mendlein John (Director) | Buy | 88,048 | 5.67 | 499,232 |
| 2022-08-18 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 5,135 | 30.08 | 154,460 |
| 2022-07-22 | Wolchko J Scott (President and CEO) | Sale | 6,246 | 32.41 | 202,414 |
| 2022-07-22 | Wolchko J Scott (President and CEO) | Option Ex | 6,246 | 2.70 | 16,864 |
| 2022-07-21 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 32.80 | 984,150 |
| 2022-07-21 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.70 | 81,000 |
| 2022-07-07 | Valamehr Bahram (Chief R&D Officer) | Sale | 17,158 | 30.23 | 518,686 |
| 2022-07-07 | Valamehr Bahram (Chief R&D Officer) | Option Ex | 17,158 | 2.73 | 46,841 |
| 2022-07-06 | Valamehr Bahram (Chief R&D Officer) | Sale | 7,842 | 30.07 | 235,808 |
| 2022-07-06 | Valamehr Bahram (Chief R&D Officer) | Option Ex | 7,842 | 3.79 | 29,681 |
| 2022-07-05 | Plavsic Mark (Chief Technical Officer) | Sale | 3,719 | 24.61 | 91,524 |
| 2022-06-07 | Agarwal Shefali (Director) | Sale | 841 | 21.89 | 18,409 |
| 2022-06-03 | Jooss Karin (Director) | Sale | 1,483 | 22.82 | 33,842 |
| 2022-06-03 | Agarwal Shefali (Director) | Sale | 807 | 22.80 | 18,399 |
| 2022-06-03 | Coughlin Timothy (Director) | Sale | 1,439 | 22.81 | 32,823 |
| 2022-06-03 | Hershberg Robert (Director) | Sale | 672 | 22.75 | 15,288 |
| 2022-06-03 | Mendlein John (Director) | Sale | 1,364 | 22.79 | 31,085 |
| 2022-06-01 | Tahl Cindy (General Counsel and Secretary) | Sale | 25,000 | 22.96 | 574,000 |
| 2022-06-01 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 25,000 | 6.55 | 163,750 |
| 2022-04-22 | Wolchko J Scott (President and CEO) | Sale | 10,000 | 34.84 | 348,450 |
| 2022-04-22 | Wolchko J Scott (President and CEO) | Option Ex | 10,000 | 2.70 | 27,000 |
| 2022-04-21 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 36.23 | 1,086,750 |
| 2022-04-21 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.70 | 81,000 |
| 2022-04-19 | Chu Yu-waye (Chief Medical Officer) | Sale | 4,062 | 35.37 | 143,672 |
| 2022-04-01 | Tahl Cindy (General Counsel and Secretary) | Sale | 25,000 | 38.85 | 971,250 |
| 2022-04-01 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 25,000 | 5.70 | 142,375 |
| 2022-03-14 | Valamehr Bahram (Chief R&D Officer) | Sale | 25,000 | 32.37 | 809,249 |
| 2022-03-14 | Valamehr Bahram (Chief R&D Officer) | Option Ex | 25,000 | 2.73 | 68,250 |
| 2022-03-10 | Mendlein John (Director) | Sale | 31,562 | 35.10 | 1,107,984 |
| 2022-03-10 | Mendlein John (Director) | Option Ex | 31,562 | 1.63 | 51,446 |
| 2022-01-21 | Wolchko J Scott (President and CEO) | Sale | 10,000 | 38.02 | 380,200 |
| 2022-01-21 | Wolchko J Scott (President and CEO) | Option Ex | 10,000 | 2.70 | 27,000 |
| 2022-01-20 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 40.21 | 1,206,300 |
| 2022-01-20 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.73 | 81,900 |
| 2022-01-11 | Chu Yu-waye (Senior VP Clinical Development) | Sale | 3,965 | 48.77 | 193,373 |
| 2022-01-11 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 1,770 | 48.70 | 86,207 |
| 2022-01-11 | Valamehr Bahram (Chief R&D Officer) | Sale | 4,570 | 48.78 | 222,924 |
| 2022-01-11 | Tahl Cindy (General Counsel and Secretary) | Sale | 5,419 | 48.80 | 264,474 |
| 2022-01-11 | Wolchko J Scott (President and CEO) | Sale | 14,566 | 48.78 | 710,602 |
| 2022-01-10 | Valamehr Bahram (Chief R&D Officer) | Sale | 5,596 | 46.75 | 261,613 |
| 2022-01-10 | Tahl Cindy (General Counsel and Secretary) | Sale | 7,738 | 46.76 | 361,828 |
| 2022-01-10 | Wolchko J Scott (President and CEO) | Sale | 34,156 | 47.08 | 1,608,166 |
| 2022-01-03 | Tahl Cindy (General Counsel and Secretary) | Sale | 50,000 | 59.19 | 2,959,600 |
| 2022-01-03 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 50,000 | 6.55 | 327,500 |
| 2021-12-20 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 15,977 | 60.00 | 958,620 |
| 2021-12-20 | Dulac Edward J Iii (Chief Financial Officer) | Option Ex | 14,437 | 35.52 | 512,802 |
| 2021-12-13 | Valamehr Bahram (Chief R&D Officer) | Sale | 25,000 | 47.61 | 1,190,150 |
| 2021-12-13 | Valamehr Bahram (Chief R&D Officer) | Option Ex | 25,000 | 2.73 | 68,250 |
| 2021-12-10 | Chu Yu-waye (Senior VP Clinical Development) | Sale | 7,500 | 52.42 | 393,180 |
| 2021-12-10 | Chu Yu-waye (Senior VP Clinical Development) | Option Ex | 7,500 | 16.32 | 122,400 |
| 2021-11-18 | Wolchko J Scott (President and CEO) | Sale | 20,000 | 54.27 | 1,085,400 |
| 2021-11-18 | Wolchko J Scott (President and CEO) | Option Ex | 20,000 | 2.70 | 54,000 |
| 2021-10-22 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 58.88 | 1,766,400 |
| 2021-10-22 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 3.42 | 102,690 |
| 2021-10-21 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 60.23 | 1,806,750 |
| 2021-10-21 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.73 | 81,900 |
| 2021-10-01 | Tahl Cindy (General Counsel and Secretary) | Sale | 50,000 | 58.89 | 2,944,600 |
| 2021-10-01 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 50,000 | 6.55 | 327,500 |
| 2021-09-28 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 19,460 | 62.53 | 1,216,833 |
| 2021-09-28 | Dulac Edward J Iii (Chief Financial Officer) | Option Ex | 17,325 | 35.52 | 615,384 |
| 2021-09-13 | Valamehr Bahram (Chief Development Officer) | Sale | 25,000 | 66.75 | 1,668,649 |
| 2021-09-13 | Valamehr Bahram (Chief Development Officer) | Option Ex | 25,000 | 2.73 | 68,250 |
| 2021-08-19 | Dulac Edward J Iii (Chief Financial Officer) | Sale | 3,474 | 88.85 | 308,664 |
| 2021-08-19 | Wolchko J Scott (President and CEO) | Sale | 20,000 | 88.01 | 1,760,200 |
| 2021-08-19 | Wolchko J Scott (President and CEO) | Option Ex | 20,000 | 4.83 | 96,700 |
| 2021-07-23 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 85.28 | 2,558,550 |
| 2021-07-23 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 3.79 | 113,550 |
| 2021-07-22 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 86.16 | 2,584,770 |
| 2021-07-22 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.73 | 81,900 |
| 2021-07-01 | Tahl Cindy (General Counsel and Secretary) | Sale | 55,534 | 89.97 | 4,996,227 |
| 2021-07-01 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 55,534 | 6.04 | 335,314 |
| 2021-06-14 | Valamehr Bahram (Chief Development Officer) | Sale | 25,000 | 89.85 | 2,246,200 |
| 2021-06-14 | Valamehr Bahram (Chief Development Officer) | Option Ex | 25,000 | 2.81 | 70,375 |
| 2021-05-20 | Wolchko J Scott (President and CEO) | Sale | 20,000 | 77.17 | 1,543,300 |
| 2021-05-20 | Wolchko J Scott (President and CEO) | Option Ex | 20,000 | 4.83 | 96,700 |
| 2021-04-23 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 85.24 | 2,557,290 |
| 2021-04-23 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 4.73 | 141,840 |
| 2021-04-22 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 85.54 | 2,566,200 |
| 2021-04-22 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.73 | 81,900 |
| 2021-04-16 | Chu Yu-waye (Senior VP Clinical Development) | Sale | 3,275 | 83.04 | 271,956 |
| 2021-03-15 | Valamehr Bahram (Chief Development Officer) | Sale | 25,000 | 92.76 | 2,319,100 |
| 2021-03-15 | Valamehr Bahram (Chief Development Officer) | Option Ex | 25,000 | 2.90 | 72,500 |
| 2021-03-08 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 25,000 | 82.55 | 2,063,725 |
| 2021-02-18 | Wolchko J Scott (President and CEO) | Sale | 20,000 | 101.28 | 2,025,600 |
| 2021-02-18 | Wolchko J Scott (President and CEO) | Option Ex | 20,000 | 6.62 | 132,400 |
| 2021-01-22 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 98.76 | 2,962,830 |
| 2021-01-22 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 4.67 | 140,250 |
| 2021-01-21 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 103.59 | 3,107,850 |
| 2021-01-21 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.73 | 81,900 |
| 2021-01-19 | Tahl Cindy (General Counsel and Secretary) | Sale | 35,000 | 115.56 | 4,044,635 |
| 2021-01-19 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 35,000 | 2.90 | 101,500 |
| 2021-01-11 | Valamehr Bahram (Chief Development Officer) | Sale | 3,254 | 110.68 | 360,139 |
| 2021-01-11 | Tahl Cindy (General Counsel and Secretary) | Sale | 3,254 | 110.68 | 360,139 |
| 2021-01-11 | Wolchko J Scott (President and CEO) | Sale | 8,587 | 110.68 | 950,374 |
| 2021-01-11 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 3,253 | 110.68 | 360,029 |
| 2021-01-08 | Valamehr Bahram (Chief Development Officer) | Sale | 6,230 | 116.33 | 724,717 |
| 2021-01-08 | Tahl Cindy (General Counsel and Secretary) | Sale | 6,229 | 116.33 | 724,600 |
| 2021-01-08 | Green Jeremy | Buy | 327,485 | 85.50 | 27,999,967 |
| 2021-01-08 | Wolchko J Scott (President and CEO) | Sale | 60,820 | 116.33 | 7,075,008 |
| 2021-01-08 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 6,229 | 116.33 | 724,600 |
| 2020-12-17 | Wolchko J Scott (President and CEO) | Sale | 20,000 | 92.28 | 1,845,660 |
| 2020-12-17 | Wolchko J Scott (President and CEO) | Option Ex | 20,000 | 6.62 | 132,400 |
| 2020-12-14 | Valamehr Bahram (Chief Development Officer) | Sale | 25,000 | 99.32 | 2,483,100 |
| 2020-12-14 | Valamehr Bahram (Chief Development Officer) | Option Ex | 25,000 | 2.90 | 72,500 |
| 2020-11-16 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 25,000 | 51.46 | 1,286,400 |
| 2020-11-13 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 51.03 | 1,530,900 |
| 2020-11-13 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 5.74 | 172,200 |
| 2020-11-12 | Wolchko J Scott (President and CEO) | Sale | 30,000 | 53.18 | 1,595,430 |
| 2020-11-12 | Wolchko J Scott (President and CEO) | Option Ex | 30,000 | 2.73 | 81,900 |
| 2020-11-05 | Tahl Cindy (General Counsel and Secretary) | Sale | 19,282 | 50.85 | 980,508 |
| 2020-11-05 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 19,282 | 2.81 | 54,278 |
| 2020-11-04 | Tahl Cindy (General Counsel and Secretary) | Sale | 51,519 | 50.41 | 2,597,124 |
| 2020-11-04 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 51,519 | 2.73 | 140,646 |
| 2020-10-16 | Tahl Cindy (General Counsel and Secretary) | Sale | 29,199 | 50.25 | 1,467,220 |
| 2020-10-16 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 29,199 | 2.73 | 79,713 |
| 2020-10-01 | Tahl Cindy (General Counsel and Secretary) | Sale | 35,000 | 41.10 | 1,438,500 |
| 2020-10-01 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 35,000 | 2.73 | 95,550 |
| 2020-09-14 | Valamehr Bahram (Chief Development Officer) | Sale | 25,000 | 36.27 | 906,850 |
| 2020-09-14 | Valamehr Bahram (Chief Development Officer) | Option Ex | 25,000 | 2.29 | 57,375 |
| 2020-09-14 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 25,000 | 36.21 | 905,250 |
| 2020-06-11 | Green Jeremy | Buy | 1,412,928 | 28.31 | 39,999,991 |
| 2020-03-30 | Rastetter William H (Director) | Option Ex | 28,461 | 1.37 | 38,991 |
| 2020-02-03 | Valamehr Bahram (Chief Development Officer) | Option Ex | 1,153 | 1.69 | 1,948 |
| 2020-01-30 | Wolchko J Scott (President and CEO) | Sale | 25,000 | 25.45 | 636,300 |
| 2020-01-30 | Wolchko J Scott (President and CEO) | Option Ex | 25,000 | 2.70 | 67,500 |
| 2020-01-08 | Valamehr Bahram (Chief Development Officer) | Sale | 5,700 | 20.69 | 117,950 |
| 2020-01-08 | Tahl Cindy (General Counsel and Secretary) | Sale | 5,700 | 20.72 | 118,086 |
| 2020-01-08 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 5,700 | 20.70 | 117,984 |
| 2019-12-30 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 25,000 | 19.92 | 497,925 |
| 2019-12-30 | Shoemaker Daniel D (Chief Scientific Officer) | Option Ex | 25,000 | 2.90 | 72,500 |
| 2019-12-20 | Wolchko J Scott (President and CEO) | Sale | 25,000 | 20.17 | 504,150 |
| 2019-12-20 | Wolchko J Scott (President and CEO) | Option Ex | 25,000 | 2.70 | 67,500 |
| 2019-12-19 | Wolchko J Scott (President and CEO) | Sale | 25,000 | 20.08 | 501,900 |
| 2019-12-19 | Wolchko J Scott (President and CEO) | Option Ex | 25,000 | 2.70 | 67,500 |
| 2019-10-15 | Valamehr Bahram (Chief Development Officer) | Sale | 6,200 | 14.18 | 87,891 |
| 2019-10-15 | Tahl Cindy (General Counsel and Secretary) | Sale | 10,200 | 14.24 | 145,288 |
| 2019-10-15 | Wolchko J Scott (President and CEO) | Sale | 21,017 | 14.44 | 303,464 |
| 2019-10-15 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 11,800 | 14.29 | 168,598 |
| 2019-09-16 | Green Jeremy | Buy | 857,143 | 17.50 | 15,000,002 |
| 2019-08-01 | Nashat Amir (Director) | Sale | 30,866 | 22.53 | 695,380 |
| 2019-07-31 | Nashat Amir (Director) | Sale | 31,139 | 22.53 | 701,686 |
| 2019-07-30 | Nashat Amir (Director) | Sale | 90,175 | 22.51 | 2,029,568 |
| 2019-07-29 | Nashat Amir (Director) | Sale | 329 | 22.50 | 7,402 |
| 2019-07-26 | Nashat Amir (Director) | Sale | 27,829 | 22.50 | 626,152 |
| 2019-07-24 | Nashat Amir (Director) | Sale | 19,866 | 22.51 | 447,104 |
| 2019-07-23 | Nashat Amir (Director) | Sale | 62,033 | 22.50 | 1,396,052 |
| 2019-07-22 | Nashat Amir (Director) | Sale | 48,704 | 22.52 | 1,097,008 |
| 2019-07-19 | Nashat Amir (Director) | Sale | 1,053 | 22.50 | 23,692 |
| 2019-07-18 | Nashat Amir (Director) | Sale | 21,409 | 22.50 | 481,788 |
| 2019-06-27 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 12,500 | 20.21 | 252,612 |
| 2019-06-27 | Shoemaker Daniel D (Chief Scientific Officer) | Option Ex | 12,500 | 2.90 | 36,250 |
| 2019-05-16 | Wolchko J Scott (President and CEO) | Sale | 14,335 | 19.00 | 272,422 |
| 2019-05-16 | Wolchko J Scott (President and CEO) | Option Ex | 14,335 | 1.63 | 23,366 |
| 2019-04-18 | Wolchko J Scott (President and CEO) | Sale | 11,459 | 16.01 | 183,504 |
| 2019-04-18 | Wolchko J Scott (President and CEO) | Option Ex | 11,459 | 1.63 | 18,678 |
| 2019-04-17 | Wolchko J Scott (President and CEO) | Sale | 8,541 | 16.14 | 137,885 |
| 2019-04-17 | Wolchko J Scott (President and CEO) | Option Ex | 8,541 | 1.63 | 13,921 |
| 2019-03-28 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 12,500 | 16.94 | 211,700 |
| 2019-03-28 | Shoemaker Daniel D (Chief Scientific Officer) | Option Ex | 12,500 | 2.90 | 36,250 |
| 2019-03-21 | Wolchko J Scott (President and CEO) | Sale | 20,000 | 17.61 | 352,160 |
| 2019-03-21 | Wolchko J Scott (President and CEO) | Option Ex | 20,000 | 1.63 | 32,599 |
| 2019-03-01 | Tahl Cindy (General Counsel and Secretary) | Sale | 25,000 | 16.15 | 403,700 |
| 2019-03-01 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 25,000 | 2.90 | 72,500 |
| 2019-02-25 | Tahl Cindy (General Counsel and Secretary) | Sale | 25,000 | 16.07 | 401,825 |
| 2019-02-25 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 25,000 | 2.90 | 72,500 |
| 2019-01-30 | Nashat Amir (Director) | Sale | 53,017 | 14.16 | 750,985 |
| 2019-01-29 | Nashat Amir (Director) | Sale | 97,500 | 14.16 | 1,380,795 |
| 2019-01-28 | Nashat Amir (Director) | Sale | 70,000 | 13.78 | 964,740 |
| 2019-01-25 | Nashat Amir (Director) | Sale | 90,000 | 14.14 | 1,272,780 |
| 2019-01-18 | Nashat Amir (Director) | Sale | 39,483 | 16.28 | 642,822 |
| 2019-01-07 | Tahl Cindy (General Counsel and Secretary) | Sale | 25,000 | 16.00 | 400,000 |
| 2019-01-07 | Tahl Cindy (General Counsel and Secretary) | Option Ex | 25,000 | 1.91 | 47,825 |
| 2018-12-20 | Nashat Amir (Director) | Sale | 33,474 | 12.25 | 410,156 |
| 2018-12-19 | Nashat Amir (Director) | Sale | 91,210 | 13.58 | 1,238,358 |
| 2018-12-13 | Nashat Amir (Director) | Sale | 17,788 | 16.67 | 296,561 |
| 2018-12-12 | Nashat Amir (Director) | Sale | 425,000 | 16.78 | 7,132,775 |
| 2018-12-11 | Nashat Amir (Director) | Sale | 82,528 | 16.71 | 1,379,207 |
| 2018-09-25 | Green Jeremy | Buy | 3,703,704 | 13.50 | 50,000,004 |
| 2018-05-15 | Abbot Stewart (Chief Development Officer) | Option Ex | 21,054 | 5.89 | 124,113 |
| 2017-10-16 | Tahl Cindy (General Counsel and Secretary) | Sale | 500 | 4.10 | 2,050 |
| 2017-10-16 | Wolchko J Scott (President and CEO) | Sale | 800 | 4.07 | 3,256 |
| 2017-10-16 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 700 | 4.08 | 2,856 |
| 2017-10-13 | Tahl Cindy (General Counsel and Secretary) | Sale | 7,591 | 3.83 | 29,073 |
| 2017-10-13 | Wolchko J Scott (President and CEO) | Sale | 16,368 | 3.87 | 63,344 |
| 2017-10-13 | Shoemaker Daniel D (Chief Scientific Officer) | Sale | 12,525 | 3.86 | 48,346 |
| 2016-11-23 | Storgard Chris (Chief Medical Officer) | Buy | 37,593 | 2.66 | 99,997 |
| 2016-11-23 | Coughlin Timothy P (Director) | Buy | 56,390 | 2.66 | 149,997 |
| 2016-11-23 | Rastetter William H (Director) | Buy | 375,939 | 2.66 | 999,997 |
| 2016-08-23 | Wolchko J Scott (President and CEO) | Option Ex | 2,570 | 1.37 | 3,520 |
| 2016-01-18 | Wolchko J Scott (President and CEO) | Option Ex | 7,500 | 1.50 | 11,250 |
| 2015-04-13 | Wolchko J Scott (See Remarks) | Option Ex | 8,000 | 1.50 | 12,000 |
| 2015-04-13 | Weyer Christian (See Remarks) | Option Ex | 25,000 | 1.37 | 34,250 |
Insider trading activities including stock purchases, stock sales, and option exercises of FATE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Fate Therapeutics Inc (symbol FATE, CIK number 1434316) see the Securities and Exchange Commission (SEC) website.